Literature DB >> 31903034

Serum Levels of Melatonin and Sleep Evaluation Scales in the Diagnosis of Sleep Disorders in Patients with Idiopathic Parkinson's Disease.

Hasan Armağan Uysal1, Bedile Irem Tıftıkcıoğlu1, Levent Öcek1, Yaşar Zorlu1.   

Abstract

INTRODUCTION: Sleep disturbances, such as difficulty in initiation of sleep, decrease in total sleep duration and efficacy, frequent awakenings, and increased daytime sleepiness are among the most common non-motor symptoms in patients with idiopathic Parkinson's disease (PD). However, patients usually do not consider these symptoms as important as their motor symptoms, and do not complain. We aimed to investigate PD patients for subtle sleep disturbances using sleep evaluation scales, and to evaluate the relationship between these tests and the serum levels of melatonin during night-sleep.
METHODS: A total of 40 PD patients (19, female), older than 50 years, registered in our "Movement Disorders Out-patient Clinic", and 40 healthy, age and sex-matched control subjects (20, female) were included in the study. All subjects were assessed using Pittsburg Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS). Serum melatonin levels during night-sleep were measured in blood samples taken at 00:00 and 05:00 hours in every subject. Both groups were compared for demographical data, sleep evaluation scales and serum levels of melatonin.
RESULTS: Patients with PD had significantly higher scores in PSQI and ESS than the healthy controls (p<0.001). Although the serum melatonin levels at two different time points during night sleep were lower in PD patients than the controls, these differences did not reach statistical significance (p=0.104 at 00:00 am, p=0.528 at 05:00 am). There was no significant correlation between the PSQI scores and serum melatonin levels in patient group (p>0.05). However, there was a significant but weak correlation (r=-0.353, p=0.025) between ESS scores and the serum melatonin levels measured at 05:00 hours in patients, but not between the melatonin levels measured at 00:00 hours.
CONCLUSION: Sleep evaluation questionnaires such as, PSQI and ESS, can provide useful information in PD patients with mild sleep disturbances. However, serum melatonin levels alone were not helpful in diagnosing the sleep disorders. Copyright:
© 2019 Turkish Neuropsychiatric Society.

Entities:  

Keywords:  Epworth Sleepiness Scale; Parkinson’s disease; Pittsburg Sleep Quality Index; melatonin; sleep disorders

Year:  2018        PMID: 31903034      PMCID: PMC6927091          DOI: 10.5152/npa.2017.19367

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  27 in total

1.  Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease.

Authors:  Aleksandar Videnovic; Charleston Noble; Kathryn J Reid; Jie Peng; Fred W Turek; Angelica Marconi; Alfred W Rademaker; Tanya Simuni; Cindy Zadikoff; Phyllis C Zee
Journal:  JAMA Neurol       Date:  2014-04       Impact factor: 18.302

Review 2.  Sleep disorders in Parkinson's disease.

Authors:  Wiebke Schrempf; Moritz D Brandt; Alexander Storch; Heinz Reichmann
Journal:  J Parkinsons Dis       Date:  2014       Impact factor: 5.568

3.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

4.  Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients.

Authors:  A T Beck; R A Steer; R Ball; W Ranieri
Journal:  J Pers Assess       Date:  1996-12

5.  Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment.

Authors:  D Kaynak; G Kiziltan; H Kaynak; G Benbir; O Uysal
Journal:  Eur J Neurol       Date:  2005-03       Impact factor: 6.089

6.  Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease.

Authors:  S J Bolitho; S L Naismith; S M W Rajaratnam; R R Grunstein; J R Hodges; Z Terpening; N Rogers; S J G Lewis
Journal:  Sleep Med       Date:  2014-01-21       Impact factor: 3.492

7.  Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists.

Authors:  Thomas Roth; David B Rye; Leona D Borchert; Cindy Bartlett; Donald L Bliwise; Charles Cantor; Jay M Gorell; Jean P Hubble; Bruno Musch; C Warren Olanow; Charles Pollak; Matt B Stern; Ray L Watts
Journal:  Sleep Med       Date:  2003-07       Impact factor: 3.492

8.  Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.

Authors:  Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle
Journal:  Mov Disord       Date:  2008-11-15       Impact factor: 10.338

Review 9.  Epidemiology and clinical features of sleep disorders in extrapyramidal disease.

Authors:  Stefania Brotini; Gian Luigi Gigli
Journal:  Sleep Med       Date:  2004-03       Impact factor: 3.492

Review 10.  Melatonin and its analogs in insomnia and depression.

Authors:  Daniel P Cardinali; Venkataramanujan Srinivasan; Amnon Brzezinski; Gregory M Brown
Journal:  J Pineal Res       Date:  2011-09-23       Impact factor: 13.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.